Neurobiology of Dopamine in Schizophrenia

International Review of Neurobiology

Volumn 78, Issue , 2007, Pages 1-39

  Guillin, Olivier ^a   Abi Dargham, Anissa ^a   Laruelle, Marc ^a  

^a New York State Psychiatric Institute ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE TRANSPORTER;

ANIMAL; BRAIN; COGNITIVE DEFECT; CORPUS STRIATUM; DRUG EFFECT; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; REVIEW; SCHIZOPHRENIA;

AMPHETAMINE; ANIMALS; BRAIN; COGNITION DISORDERS; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; PREFRONTAL CORTEX; RECEPTORS, DOPAMINE; SCHIZOPHRENIA;

EID: 33847409606     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7742(06)78001-1     Document Type: Review

References (223)

1. Abi-Dargham A., and Laruelle M. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: Insights from brain imaging studies. Eur. Psychiatry 20 (2005) 15-27
2. Abi-Dargham A., Gil R., Krystal J., Baldwin R., Seibyl J., Bowers M., van Dyck C., Charney D., Innis R., and Laruelle M. Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort. Am. J. Psychiatry 155 (1998) 761-767
3. Abi-Dargham A., Martinez D., Mawlawi O., Simpson N., Hwang D.R., Slifstein M., Anjilvel S., Pidcock J., Guo N.N., Lombardo I., Mann J.J., Van Heertum R., et al. Measurement of striatal and extrastriatal dopamine D1 receptor binding potential with [11C]NNC 112 in humans: Validation and reproducibility. J. Cereb. Blood Flow Metab. 20 (2000) 225-243
4. Abi-Dargham A., Rodenhiser J., Printz D., Zea-Ponce Y., Gil R., Kegeles L., Weiss R., Cooper T., Mann J.J., Van Heertum R., Gorman J., and Laruelle M. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc. Natl. Acad. Sci. USA 97 (2000) 8104-8109
5. Abi-Dargham A., Mawlawi O., Lombardo I., Gil R., Martinez D., Huang Y., Hwang D.R., Keilp J., Kochan L., Van Heertum R., Gorman J.M., and Laruelle M. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J. Neurosci. 22 (2002) 3708-3719
6. Akil M., Pierri J.N., Whitehead R.E., Edgar C.L., Mohila C., Sampson A.R., and Lewis D.A. Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am. J. Psychiatry 156 (1999) 1580-1589
7. Akil M., Edgar C.L., Pierri J.N., Casali S., and Lewis D.A. Decreased density of tyrosine hydroxylase-immunoreactive axons in the entorhinal cortex of schizophrenic subjects. Biol. Psychiatry 47 (2000) 361-370
8. Albin R.L., Young A.B., and Penney J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci. 12 (1989) 366-375
9. Alexander G.E., DeLong M.R., and Strick P.L. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu. Rev. Neurosci. 9 (1986) 357-381
10. Angrist B.M., and Gershon S. The phenomenology of experimentally induced amphetamine psychosis: Preliminary observation. Biol. Psychiatry 2 (1970) 95-107
11. Angrist B.M., and van Kammen D.P. CNS stimulants as a tool in the study of schizophrenia. Trends Neurosci. 7 (1984) 388-390
12. Bell D.S. The experimental reproduction of amphetamine psychosis. Arch. Gen. Psychiatry 29 (1973) 35-40
13. Benes F.M., Todtenkopf M.S., and Taylor J.B. Differential distribution of tyrosine hydroxylase fibres on small and large neurons in layer II of anterior cingulate cortex of schizophrenic brain. Synapse 25 1 (1997) 80-92
14. Blin J., Baron J.C., Cambon H., Bonnet A.M., Dubois B., Loc'h C., Maziere B., and Agid Y. Striatal dopamine D2 receptors in tardive dyskinesia: PET study. J. Neurol. Neurosurg. Psychiatry 52 (1989) 1248-1252
15. Boileau I., Dagher A., Leyton M., Gunn R., Diksic M., and Benkelfat C. Sensitization to psychostimulants: A PET/[11C]-raclopride study in healthy volunteers. ACNP Annual Meting Abstracts. (2003)
16. Bordet R., Ridray S., Carboni S., Diaz J., Sokoloff P., and Schwartz J.C. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc. Natl. Acad. Sci. USA 94 (1997) 3363-3367
17. Breier A., Su T.P., Saunders R., Carson R.E., Kolachana B.S., de Bartolomeis A., Weinberger D.R., Weisenfeld N., Malhotra A.K., Eckelman W.C., and Pickar D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. Proc. Natl. Acad. Sci. USA 94 (1997) 2569-2574
18. Bunzow J.R., Van Tol H.H., Grandy D.K., Albert P., Salon J., Christie M., Machida C.A., Neve K.A., and Civelli O. Cloning and expression of a rat D2 dopamine receptor cDNA. Nature 336 (1988) 783-787
19. Burt D.R., Creese I., and Snyder S.H. Antischizophrenic drugs: Chronic treatment elevates dopamine receptor binding in brain. Science 196 (1977) 326-328
20. Carlsson A., and Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol. Toxicol. 20 (1963) 140-144
21. Carlsson A., Waters N., Holm-Waters S., Tedroff J., Nilsson M., and Carlsson M.L. Interactions between monoamines, glutamate, and GABA in schizophrenia: New evidence. Annu. Rev. Pharmacol. Toxicol. 41 (2001) 237-260
22. Centonze D., Picconi B., Gubellini P., Bernardi G., and Calabresi P. Dopaminergic control of synaptic plasticity in the dorsal striatum. Eur. J. Neurosci. 13 (2001) 1071-1077
23. Cepeda C., and Levine M.S. Dopamine and N-methyl-D-aspartate receptor interactions in the neostriatum. Dev. Neurosci. 20 (1998) 1-18
24. Cepeda C., Hurst R.S., Altemus K.L., Flores-Hernandez J., Calvert C.R., Jokel E.S., Grandy D.K., Low M.J., Rubinstein M., Ariano M.A., and Levine M.S. Facilitated glutamatergic transmission in the striatum of D2 dopamine receptor-deficient mice. J. Neurophysiol. 85 (2001) 659-670
25. Chinaglia G., Alvarez F.J., Probst A., and Palacios J.M. Mesostriatal and mesolimbic dopamine uptake binding sites are reduced in Parkinson's disease and progressive supranuclear palsy: A quantitative autoradiographic study using [3H]mazindol. Neuroscience 49 (1992) 317-327
26. Chiodo L.A., and Bunney B.S. Typical and atypical neuroleptics: Differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J. Neurosci. 3 (1983) 1607-1619
27. Cho S., Neff N.H., and Hadjiconstantinou M. Regulation of tyrosine hydroxylase and aromatic L-amino acid decarboxylase by dopaminergic drugs. Eur. J. Pharmacol. 323 (1997) 149-157
28. Civelli O., Bunzow J.R., and Grandy D.K. Molecular diversity of the dopamine receptors. Annu. Rev. Pharmacol. Toxicol. 33 (1993) 281-307
29. Connell P.H. "Amphetamine Psychosis." (1958), Chapman and Hill, London
30. Crawley J.C., Owens D.G., Crow T.J., Poulter M., Johnstone E.C., Smith T., Oldland S.R., Veall N., Owen F., and Zanelli G.D. Dopamine D2 receptors in schizophrenia studied in vivo. Lancet 2 (1986) 224-225
31. Creese I., Burt D.R., and Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 19 (1976) 481-483
32. Cross A.J., Crow T.J., Ferrier I.N., Johnstone E.C., McCreadie R.M., Owen F., Owens D.G., and Poulter M. Dopamine receptor changes in schizophrenia in relation to the disease process and movement disorder. J. Neural. Transm. Suppl. 18 (1983) 265-272
33. Crow T.J. Molecular pathology of schizophrenia: More than one disease process?. Br. Med. J. 280 (1980) 66-68
34. Czudek C., and Reynolds G.P. [3H] GBR 12935 binding to the dopamine uptake site in post-mortem brain tissue in schizophrenia. J. Neural. Transm. 77 (1989) 227-230
35. Daniel D.G., Weinberger D.R., Jones D.W., Zigun J.R., Coppola R., Handel S., Bigelow L.B., Goldberg T.E., Berman K.F., and Kleinman J.E. The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J. Neurosci. 11 (1991) 1907-1917
36. Danielsen E.H., Smith D., Hermansen F., Gjedde A., and Cumming P. Acute neuroleptic stimulates DOPA decarboxylase in porcine brain in vivo. Synapse 41 (2001) 172-175
37. Dao-Castellana M.H., Paillere-Martinot M.L., Hantraye P., Attar-Levy D., Remy P., Crouzel C., Artiges E., Feline A., Syrota A., and Martinot J.L. Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophr. Res. 23 (1997) 167-174
38. Davis K.L., Kahn R.S., Ko G., and Davidson M. Dopamine in schizophrenia: A review and reconceptualization. Am. J. Psychiatry 148 (1991) 1474-1486
39. Dean B., Pavey G., and Opeskin K. [3H]raclopride binding to brain tissue from subjects with schizophrenia: Methodological aspects. Neuropharmacology 36 (1997) 779-786
40. Dearry A., Gingrich J.A., Falardeau P., Fremeau Jr. R.T., Bates M.D., and Caron M.G. Molecular cloning and expression of the gene for a human D1 dopamine receptor. Nature 347 (1990) 72-76
41. Delay J., Deniker P., and Harl J. Therapeutic use in psychiatry of phenothiazine of central elective action (4560 RP). Ann. Med. Psychol. Paris 110 2:1 (1952) 112-117
42. DeLong M.R., Crutcher M.D., and Georgopoulos A.P. Primate globus pallidus and subthalamic nucleus: Functional organization. J. Neurophysiol. 53 (1985) 530-543
43. Deutch A.Y., Clark W.A., and Roth R.H. Prefrontal cortical dopamine depletion enhances the responsiveness of the mesolimbic dopamine neurons to stress. Brain Res. 521 (1990) 311-315
44. Deutch A.Y., Moghaddam B., Innis R.B., Krystal J.H., Aghajanian G.K., Bunney B.S., and Charney D.S. Mechanisms of action of atypical antipsychotic drugs. Implications for novel therapeutic strategies for schizophrenia. Schizophr. Res. 4 (1991) 121-156
45. Diaz J., Levesque D., Lammers C.H., Griffon N., Martres M.P., Schwartz J.C., and Sokoloff P. Phenotypical characterization of neurons expressing the dopamine D3 receptor in the rat brain. Neuroscience 65 (1995) 731-745
46. Diaz J., Pilon C., Le Foll B., Gros C., Triller A., Schwartz J.C., and Sokoloff P. Dopamine D3 receptors expressed by all mesencephalic dopamine neurons. J. Neurosci. 20 (2000) 8677-8684
47. Dolan R.J., Fletcher P., Frith C.D., Friston K.J., Frackowiak R.S., and Grasby P.M. Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia. Nature 378 (1995) 180-182
48. Dumartin B., Jaber M., Gonon F., Caron M.G., Giros B., and Bloch B. Dopamine tone regulates D1 receptor trafficking and delivery in striatal neurons in dopamine transporter-deficient mice. Proc. Natl. Acad. Sci. USA 97 (2000) 1879-1884
49. Dunah A.W., and Standaert D.G. Dopamine D1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane. J. Neurosci. 21 (2001) 5546-5558
50. Elkashef A.M., Doudet D., Bryant T., Cohen R.M., Li S.H., and Wyatt R.J. 6-(18)F-DOPA PET study in patients with schizophrenia. Positron emission tomography. Psychiatry Res. 100 (2000) 1-11
51. Ellinwood Jr. E.H. Amphetamine psychosis: I. Description of the individuals and process. J. Nerv. Ment. Dis. 144 (1967) 273-283
52. Ellinwood Jr. E.H., Sudilovsky A., and Nelson L.M. Evolving behavior in the clinical and experimental amphetamine model psychosis. Am. J. Psychiatry 130 (1973) 1088-1093
53. Everitt B.J., Morris K.A., O'Brien A., and Robbins T.W. The basolateral amygdala-ventral striatal system and conditioned place preference: Further evidence of limbic-striatal interactions underlying reward-related processes. Neuroscience 42 (1991) 1-18
54. Farde L., Wiesel F., Stone-Elander S., Halldin C., Nordsröm A.L., Hall H., and Sedvall G. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. Arch. Gen. Psychiatry 47 (1990) 213-219
55. Farde L., Nordström A.L., Wiesel F.A., Pauli S., Halldin C., and Sedvall G. Positron emission tomography analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch. Gen. Psychiatry 49 (1992) 538-544
56. Fauchey V., Jaber M., Caron M.G., Bloch B., and Le Moine C. Differential regulation of the dopamine D1, D2 and D3 receptor gene expression and changes in the phenotype of the striatal neurons in mice lacking the dopamine transporter. Eur. J. Neurosci. 12 (2000) 19-26
57. Ferry A.T., Ongur D., An X., and Price J.L. Prefrontal cortical projections to the striatum in macaque monkeys: Evidence for an organization related to prefrontal networks. J. Comp. Neurol. 425 (2000) 447-470
58. Flores-Hernandez J., Cepeda C., Hernandez-Echeagaray E., Calvert C.R., Jokel E.S., Fienberg A.A., Greengard P., and Levine M.S. Dopamine enhancement of NMDA currents in dissociated medium-sized striatal neurons: Role of D1 receptors and DARPP-32. J. Neurophysiol. 88 (2002) 3010-3020
59. Frankle W.G., Gil R., Hackett E., Mawlawi O., Zea-Ponce Y., Zhu Z., Kochan L.D., Cangiano C., Slifstein M., Gorman J.M., Laruelle M., and Abi-Dargham A. Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: Theoretical implications. Psychopharmacology (Berl.) 175 (2004) 473-480
60. Gerfen C.R. The neostriatal mosaic: Multiple levels of compartmental organization in the basal ganglia. Annu. Rev. Neurosci. 15 (1992) 285-320
61. Gessa G.L., Devoto P., Diana M., Flore G., Melis M., and Pistis M. Dissociation of haloperidol, clozapine, and olanzapine effects on electrical activity of mesocortical dopamine neurons and dopamine release in the prefrontal cortex. Neuropsychopharmacology 22 (2000) 642-649
62. Gingrich J.A., and Caron M.G. Recent advances in the molecular biology of dopamine receptors. Annu. Rev. Neurosci. 16 (1993) 299-321
63. Glenthoj B.Y., and Hemmingsen R. Dopaminergic sensitization: Implications for the pathogenesis of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 21 (1997) 23-46
64. Goldberg T.E., and Weinberger D.R. Genes and the parsing of cognitive processes. Trends Cogn. Sci. 8 (2004) 325-335
65. Goldman-Rakic P. Working memory dysfunction in schizophrenia. J. Neuropsychiatry Clin. Neurosci. 6 (1994) 348
66. Goldman-Rakic P.S., Muly III E.C., and Williams G.V. D(1) receptors in prefrontal cells and circuits. Brain Res. Brain Res. Rev. 31 (2000) 295-301
67. Grace A.A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia. Neuroscience 41 (1991) 1-24
68. Grace A.A. Gating of information flow within the limbic system and the pathophysiology of schizophrenia. Brain Res. Brain Res. Rev. 31 (2000) 330-341
69. Griffith J.J., Oates J., and Cavanaugh J. Paranoid episodes induced by drugs. J. Am. Med. Assoc. 205 (1968) 39
70. Grunder G., Vernaleken I., Muller M.J., Davids E., Heydari N., Buchholz H.G., Bartenstein P., Munk O.L., Stoeter P., Wong D.F., Gjedde A., and Cumming P. Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo. Neuropsychopharmacology 28 (2003) 787-794
71. Guillin O., Diaz J., Carroll P., Griffon N., Schwartz J.C., and Sokoloff P. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 411 (2001) 86-89
72. Guo N., Hwang D., Abdellhadi S., Abi-Dargham A., Zarahn E., and Laruelle M. The effect of chronic DA depletion on D1 ligand binding in rodent brain. Soc. Neurosc. Abst. 27 (2001)
73. Gurevich E.V., Bordelon Y., Shapiro R.M., Arnold S.E., Gur R.E., and Joyce J.N. Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. Arch. Gen. Psychiatry 54 (1997) 225-232
74. Haber S.N., and Fudge J.L. The primate substantia nigra and VTA: Integrative circuitry and function. Crit. Rev. Neurobiol. 11 (1997) 323-342
75. Haber S.N., Fudge J.L., and McFarland N.R. Striatonigrostriatal pathways in primates form an ascending spiral from the shell to the dorsolateral striatum. J. Neurosci. 20 (2000) 2369-2382
76. Hashimoto T., Bergen S.E., Nguyen Q.L., Xu B., Monteggia L.M., Pierri J.N., Sun Z., Sampson A.R., and Lewis D.A. Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J. Neurosci. 25 (2005) 372-383
77. Hernandez-Lopez S., Bargas J., Surmeier D.J., Reyes A., and Galarraga E. D1 receptor activation enhances evoked discharge in neostriatal medium spiny neurons by modulating an L-type Ca2+ conductance. J. Neurosci. 17 (1997) 3334-3342
78. Hersch S.M., Ciliax B.J., Gutekunst C.A., Rees H.D., Heilman C.J., Yung K.K., Bolam J.P., Ince E., Yi H., and Levey A.I. Electron microscopic analysis of D1 and D2 dopamine receptor proteins in the dorsal striatum and their synaptic relationships with motor corticostriatal afferents. J. Neurosci. 15 (1995) 5222-5237
79. Hess E.J., Bracha H.S., Kleinman J.E., and Creese I. Dopamine receptor subtype imbalance in schizophrenia. Life Sci. 40 (1987) 1487-1497
80. Hietala J., Syvälahti E., Vuorio K., Nagren K., Lehikoinen P., Ruotsalainen U., Räkköläinen V., Lehtinen V., and Wegelius U. Striatal D2 receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. Arch. Gen. Psychiatry 51 (1994) 116-123
81. Hietala J., West C., Syvalahti E., Nagren K., Lehikoinen P., Sonninen P., and Ruotsalainen U. Striatal D2 dopamine receptor binding characteristics in vivo in patients with alcohol dependence. Psychopharmacology (Berl.) 116 (1994) 285-290
82. Hietala J., Syvalahti E., Vuorio K., Rakkolainen V., Bergman J., Haaparanta M., Solin O., Kuoppamaki M., Kirvela M., Ruotsalainen U., and Salokangas R.K.R. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 346 (1995) 1130-1131
83. Hietala J., Syvalahti E., Vilkman H., Vuorio K., Rakkolainen V., Bergman J., Haaparanta M., Solin O., Kuoppamaki M., Eronen E., Ruotsalainen U., and Salokangas R.K. Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schizophr. Res. 35 (1999) 41-50
84. Hirai M., Kitamura N., Hashimoto T., Nakai T., Mita T., Shirakawa O., Yamadori T., Amano T., Noguchi-Kuno S.A., and Tanaka C. [3H]GBR-12935 binding sites in human striatal membranes: Binding characteristics and changes in parkinsonians and schizophrenics. Jpn. J. Pharmacol. 47 (1988) 237-243
85. Hirvonen J., van Erp T.G., Huttunen J., Aalto S., Nagren K., Huttunen M., Lonnqvist J., Kaprio J., Hietala J., and Cannon T.D. Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia. Arch. Gen. Psychiatry 62 (2005) 371-378
86. Hoover J.E., and Strick P.L. Multiple output channels in the basal ganglia. Science 259 (1993) 819-821
87. Hsiao M.C., Lin K.J., Liu C.Y., Tzen K.Y., and Yen T.C. Dopamine transporter change in drug-naive schizophrenia: An imaging study with 99mTc-TRODAT-1. Schizophr. Res. 65 (2003) 39-46
88. Ichikawa J., Ishii H., Bonaccorso S., Fowler W.L., O'Laughlin I.A., and Meltzer H.Y. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: A possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem. 76 (2001) 1521-1531
89. Joel D., and Weiner I. The connections of the dopaminergic system with the striatum in rats and primates: An analysis with respect to the functional and compartmental organization of the striatum. Neuroscience 96 (2000) 451-474
90. Joyce J.N., and Meador-Woodruff J.H. Linking the family of D-2 receptors to neuronal circuits in human brain: Insights into schizophrenia. Neuropsychopharmacology 16 (1997) 375-384
91. Joyce J.N., Lexow N., Bird E., and Winokur A. Organization of dopamine D1 and D2 receptors in human striatum: Receptor autoradiographic studies in Huntington's disease and schizophrenia. Synapse 2 (1988) 546-557
92. Kahn R.S., Harvey P.D., Davidson M., Keefe R.S., Apter S., Neale J.M., Mohs R.C., and Davis K.L. Neuropsychological correlates of central monoamine function in chronic schizophrenia: Relationship between CSF metabolites and cognitive function. Schizophr. Res. 11 (1994) 217-224
93. Kalivas P.W., Sorg B.A., and Hooks M.S. The pharmacology and neural circuitry of sensitization to psychostimulants. Behav. Pharmacol. 4 (1993) 315-334
94. Kapur S. Psychosis as a state of aberrant salience: A framework linking biology, phenomenology, and pharmacology in schizophrenia. Am. J. Psychiatry 160 (2003) 13-23
95. Kapur S., Zipursky R., Jones C., Remington G., and Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry 157 (2000) 514-520
96. Karlsson P., Farde L., Halldin C., and Sedvall G. PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. Am. J. Psychiatry 159 (2002) 761-767
97. Karreman M., and Moghaddam B. The prefrontal cortex regulates the basal release of dopamine in the limbic striatum: An effect mediated by ventral tegmental area. J. Neurochem. 66 (1996) 589-598
98. Kebabian J.W., and Calne D.B. Multiple receptors for dopamine. Nature 277 (1979) 93-96
99. Keefe R.S., Silva S.G., Perkins D.O., and Lieberman J.A. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis. Schizophr. Bull. 25 (1999) 201-222
100. Knable M.B., and Weinberger D.R. Dopamine, the prefrontal cortex and schizophrenia. J. Psychopharmacol. 11 (1997) 123-131
101. Knable M.B., Hyde T.M., Herman M.M., Carter J.M., Bigelow L., and Kleinman J.E. Quantitative autoradiography of dopamine-D1 receptors, D2 receptors, and dopamine uptake sites in postmortem striatal specimens from schizophrenic patients. Biol. Psychiatry 36 (1994) 827-835
102. Knable M.B., Hyde T.M., Murray A.M., Herman M.M., and Kleinman J.E. A postmortem study of frontal cortical dopamine D1 receptors in schizophrenics, psychiatric controls, and normal controls. Biol. Psychiatry 40 (1996) 1191-1199
103. Knable M.B., Egan M.F., Heinz A., Gorey J., Lee K.S., Coppola R., and Weinberger D.R. Altered dopaminergic function and negative symptoms in drug-free patients with schizophrenia. [123I]-iodobenzamide SPECT study. Br. J. Psychiatry 171 (1997) 574-577
104. Kolachana B.S., Saunders R., and Weinberger D. Augmentation of prefrontal cortical monoaminergic activity inhibits dopamine release in the caudate nucleus: An in vivo neurochemical assessment in the rhesus monkey. Neurosciences 69 (1995) 859-868
105. Konradi C. The molecular basis of dopamine and glutamate interactions in the striatum. Adv. Pharmacol. 42 (1998) 729-733
106. Konradi C., and Heckers S. Molecular aspects of glutamate dysregulation: Implications for schizophrenia and its treatment. Pharmacol. Ther. 97 (2003) 153-179
107. Kotter R. Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum. Prog. Neurobiol. 44 (1994) 163-196
108. Kramer M.S., Last B., Getson A., and Reines S.A. The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group. Arch. Gen. Psychiatry 54 (1997) 567-572
109. Kunishio K., and Haber S.N. Primate cingulostriatal projection: Limbic striatal versus sensorimotor striatal input. J. Comp. Neurol. 350 (1994) 337-356
110. Laakso A., Vilkman H., Alakare B., Haaparanta M., Bergman J., Solin O., Peurasaari J., Rakkolainen V., Syvalahti E., and Hietala J. Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography. Am. J. Psychiatry 157 (2000) 269-271
111. Lahti R.A., Roberts R.C., Conley R.R., Cochrane E.V., Mutin A., and Tamminga C.A. D2-type dopamine receptors in postmortem human brain sections from normal and schizophrenic subjects. Neuroreport 7 (1996) 1945-1948
112. Lahti R.A., Roberts R.C., Cochrane E.V., Primus R.J., Gallager D.W., Conley R.R., and Tamminga C.A. Direct determination of dopamine D4 receptors in normal and schizophrenic postmortem brain tissue: A [3H]NGD-94-1 study. Mol. Psychiatry 3 (1998) 528-533
113. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: A critical review. J. Cereb. Blood Flow Metab. 20 (2000) 423-451
114. Laruelle M. The role of endogenous sensitization in the pathophysiology of schizophrenia: Implications from recent brain imaging studies. Brain Res. Rev. 31 (2000) 371-384
115. Laruelle M., Casanova M., Weinberger D., and Kleinman J. Postmortem study of the dopaminergic D1 receptors in the dorsolateral prefrontal cortex of schizophrenics and controls. Schizophr. Res 3 (1990) 30-31
116. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., McCance E., Rosenblatt W., Fingado C., Zoghbi S.S., Baldwin R.M., Seibyl R.M., et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci. USA 93 (1996) 9235-9240
117. Laruelle M., D'Souza C.D., Baldwin R.M., Abi-Dargham A., Kanes S.J., Fingado C.L., Seibyl J.P., Zoghbi S.S., Bowers M.B., Jatlow P., Charney D.S., and Innis R.B. Imaging D-2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 17 (1997) 162-174
118. Laruelle M., Iyer R.N., al-Tikriti M.S., Zea-Ponce Y., Malison R., Zoghbi S.S., Baldwin R.M., Kung H.F., Charney D.S., Hoffer P.B., Innis R.B., and Bradberry C.W. Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 25 (1997) 1-14
119. Laruelle M., Abi-Dargham A., Gil R., Kegeles L., and Innis R. Increased dopamine transmission in schizophrenia: Relationship to illness phases. Biol. Psychiatry 46 (1999) 56-72
120. 123I]beta-CIT. Biol. Psychiatry 47 (2000) 371-379
121. Laruelle M., Abi-Dargham A., van Dyck C., Gil R., D'Souza D.C., Krystal J., Seibyl J., Baldwin R., and Innis R. Dopamine and serotonin transporters in patients with schizophrenia: An imaging study with [(123)I]beta-CIT. Biol. Psychiatry 47 (2000) 371-379
122. Le Foll B., Frances H., Diaz J., Schwartz J.C., and Sokoloff P. Role of the dopamine D3 receptor in reactivity to cocaine-associated cues in mice. Eur. J. Neurosci. 15 (2002) 2016-2026
123. Le Moine C., Tison F., and Bloch B. D2 dopamine receptor gene expression by cholinergic neurons in the rat striatum. Neurosci. Lett. 117 (1990) 248-252
124. Le Moine C., Normand E., and Bloch B. Phenotypical characterization of the rat striatal neurons expressing the D1 dopamine receptor gene. Proc. Natl. Acad. Sci. USA 88 (1991) 4205-4209
125. Lee T., Seeman P., Tourtellotte W.W., Farley I.J., and Hornykeiwicz O. Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains. Nature 274 (1978) 897-900
126. Leveque J.C., Macias W., Rajadhyaksha A., Carlson R.R., Barczak A., Kang S., Li X.M., Coyle J.T., Huganir R.L., Heckers S., and Konradi C. Intracellular modulation of NMDA receptor function by antipsychotic drugs. J. Neurosci. 20 (2000) 4011-4020
127. Levine M.S., Li Z., Cepeda C., Cromwell H.C., and Altemus K.L. Neuromodulatory actions of dopamine on synaptically-evoked neostriatal responses in slices. Synapse 24 (1996) 65-78
128. Lieberman J.A., Kane J.M., and Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology 91 (1987) 415-433
129. Lieberman J.A., Kane J.M., Sarantakos S., Gadaleta D., Woerner M., Alvir J., and Ramos-Lorenzi J. Prediction of relapse in schizophrenia. Arch. Gen. Psychiatry 44 (1987) 597-603
130. Lieberman J.A., Kinon B.L., and Loebel A.D. Dopaminergic mechanisms in idiopathic and drug-induced psychoses. Schizophr. Bull. 16 (1990) 97-110
131. Lieberman J.A., Sheitman B.B., and Kinon B.J. Neurochemical sensitization in the pathophysiology of schizophrenia: Deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology 17 (1997) 205-229
132. Lindstrom L.H., Gefvert O., Hagberg G., Lundberg T., Bergstrom M., Hartvig P., and Langstrom B. Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. Biol. Psychiatry 46 (1999) 681-688
133. Lindvall O., and Björklund A. Dopamine- and norepinephrine-containing neuron systems: Their anatomy in the rat brain. In: Emson P. (Ed). "Chemical Neuroanatomy" (1983), Raven Press, New York 229-255
134. Mackay A.V., Iversen L.L., Rossor M., Spokes E., Bird E., Arregui A., Creese I., and Synder S.H. Increased brain dopamine and dopamine receptors in schizophrenia. Arch. Gen. Psychiatry 39 (1982) 991-997
135. Marti M., Mela F., Bianchi C., Beani L., and Morari M. Striatal dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: Opposite role for D1 and D2 receptors. J. Neurochem. 83 (2002) 635-644
136. Martinot J.-L., Peron-Magnan P., Huret J.-D., Mazoyer B., Baron J.-C., Boulenger J.-P.C., Lh B.M., Caillard V.H.L., and Syrota A. Striatal D2 dopaminergic receptors assessed with positron emission tomography and 76-Br-bromospiperone in untreated patients. Am. J. Psychiatry 147 (1990) 346-350
137. Martinot J.L., Paillère-Martinot M.L., Loc'h C., Hardy P., Poirier M.F., Mazoyer B., Beaufils B., Mazière B., Alliaire J.F., and Syrota A. The estimated density of D2 striatal receptors in schizophrenia. A study with positron emission tomography and 76Br-bromolisuride. Br. J. Psychiatry 158 (1991) 346-350
138. Martinot J.L., Paillère-Martinot M.L., Loch'H C., Lecrubier Y., Dao-Castellana M.H., Aubin F., Allilaire J.F., Mazoyer B., Mazière B., and Syrota A. Central D2 receptors and negative symptoms of schizophrenia. Br. J. Pharmacol. 164 (1994) 27-34
139. Marzella P.L., Hill C., Keks N., Singh B., and Copolov D. The binding of both [3H]nemonapride and [3H]raclopride is increased in schizophrenia. Biol. Psychiatry 42 (1997) 648-654
140. McGowan S.W., Lawrence A., Sale T., Quested D., and Grasby P.M. Presynaptic dopaminergic dysfunction in medicated schizophrenic patients. Arch. Gen. Psychiatry 61 (2004) 134-142
141. Meador-Woodruff J.H., Damask S.P., Wang J., Haroutunian V., Davis K.L., and Watson S.J. Dopamine receptor mRNA expression in human striatum and neocortex. Neuropsychopharmacology 15 (1996) 17-29
142. Melis M., Diana M., and Gessa G.L. Clozapine potently stimulates mesocortical dopamine neurons. Eur. J. Pharmacol. 366 (1999) R11-R13
143. Meyer-Lindenberg A., Miletich R.S., Kohn P.D., Esposito G., Carson R.E., Quarantelli M., Weinberger D.R., and Berman K.F. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat. Neurosci. 5 (2002) 267-271
144. Missale C., Nash S.R., Robinson S.W., Jaber M., and Caron M.G. Dopamine receptors: From structure to function. Physiol. Rev. 78 (1998) 189
145. Mita T., Hanada S., Nishino N., Kuno T., Nakai H., Yamadori T., Mizoi Y., and Tanaka C. Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics. Biol. Psychiatry 21 (1986) 1407-1414
146. Mogenson G.J., Jones D.L., and Yim C.Y. From motivation to action: Functional interface between the limbic system and the motor system. Prog. Neurobiol. 14 (1980) 69-97
147. Monsma Jr. F.J., Mahan L.C., McVittie L.D., Gerfen C.R., and Sibley D.R. Molecular cloning and expression of a D1 dopamine receptor linked to adenylyl cyclase activation. Proc. Natl. Acad. Sci. USA 87 (1990) 6723-6727
148. Morari M., O'Connor W.T., Ungerstedt U., and Fuxe K. Dopamine D1 and D2 receptor antagonism differentially modulates stimulation of striatal neurotransmitter levels by N-methyl-D-aspartic acid. Eur. J. Pharmacol. 256 (1994) 23-30
149. Mrzljak L., Bergson C., Pappy M., Huff R., Levenson R., and Goldman-Rakic P.S. Localization of dopamine D4 receptors in GABAergic neurons of the primate brain. Nature 381 (1996) 245-248
150. Murray A.M., Hyde T.M., Knable M.B., Herman M.M., Bigelow L.B., Carter J.M., Weinberger D.R., and Kleinman J.E. Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia. J. Neurosci. 15 (1995) 2186-2191
151. Nguyen T.V., Kosofsky B.E., Birnbaum R., Cohen B.M., and Hyman S.E. Differential expression of c-fos and zif268 in rat striatum after haloperidol, clozapine, and amphetamine. Proc. Natl. Acad. Sci. USA 89 (1992) 4270-4274
152. Nicola S.M., Surmeier J., and Malenka R.C. Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens. Annu. Rev. Neurosci. 23 (2000) 185-215
153. Nishi A., Snyder G.L., and Greengard P. Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J. Neurosci. 17 (1997) 8147-8155
154. Nordstrom A.L., Farde L., Wiesel F.A., Forslund K., Pauli S., Halldin C., and Uppfeldt G. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients. Biol. Psychiatry 33 (1993) 227-235
155. Nordstrom A.L., Farde L., Eriksson L., and Halldin C. No elevated D2 dopamine receptors in neuroleptic-naive schizophrenic patients revealed by positron emission tomography and [11C]N-methylspiperone [see comments]. Psychiatry Res. 61 (1995) 67-83
156. Okubo Y., Suhara T., Suzuki K., Kobayashi K., Inoue O., Terasaki O., Someya Y., Sassa T., Sudo Y., Matsushima E., Iyo M., Tateno Y., et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 385 (1997) 634-636
157. Onn S.P., West A.R., and Grace A.A. Dopamine-mediated regulation of striatal neuronal and network interactions. Trends Neurosci. 23 (2000) S48-S56
158. Owen F., Cross A.J., Crow T.J., Longden A., Poulter M., and Riley G.J. Increased dopamine-receptor sensitivity in schizophrenia. Lancet 2 (1978) 223-226
159. Palermo-Neto J. Dopaminergic systems. Dopamine receptors. Psychiatr. Clin. North Am. 20 (1997) 705-721
160. Parent A., and Hazrati L.N. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res. Brain Res. Rev. 20 (1995) 91-127
161. Parsey R.V., Oquendo M.A., Zea-Ponce Y., Rodenhiser J., Kegeles L.S., Pratap M., Cooper T.B., Van Heertum R., Mann J.J., and Laruelle M. Dopamine D(2) receptor availability and amphetamine-induced dopamine release in unipolar depression. Biol. Psychiatry 50 (2001) 313-322
162. Pearce R.K., Seeman P., Jellinger K., and Tourtellotte W.W. Dopamine uptake sites and dopamine receptors in Parkinson's disease and schizophrenia. Eur. Neurol. 30 Suppl. 1 (1990) 9-14
163. Pehek E.A., and Yamamoto B.K. Differential effects of locally administered clozapine and haloperidol on dopamine efflux in the rat prefrontal cortex and caudate-putamen. J. Neurochem. 63 (1994) 2118-2124
164. Pennartz C.M., Groenewegen H.J., and Lopes da Silva F.H. The nucleus accumbens as a complex of functionally distinct neuronal ensembles: An integration of behavioural, electrophysiological and anatomical data. Prog. Neurobiol. 42 (1994) 719-761
165. Peris J., Dwoskin L.P., and Zahniser N.R. Biphasic modulation of evoked [3H]D-aspartate release by D-2 dopamine receptors in rat striatal slices. Synapse 2 (1988) 450-456
166. Pilowsky L.S., Costa D.C., Ell P.J., Verhoeff N.P., Murray R.M., and Kerwin R.W. D2 dopamine receptor binding in the basal ganglia of antipsychotic-free schizophrenic patients. An 123I-IBZM single photon emission computerised tomography study. Br. J. Psychiatry 164 (1994) 16-26
167. Pimoule C., Schoemaker H., Reynolds G.P., and Langer S.Z. [3H]SCH 23390 labeled D1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease. Eur. J. Pharmacol. 114 (1985) 235-237
168. Pycock C.J., Kerwin R.W., and Carter C.J. Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature 286 (1980) 74-77
169. Reith J., Benkelfat C., Sherwin A., Yasuhara Y., Kuwabara H., Andermann F., Bachneff S., Cumming P., Diksic M., Dyve S.E., Etienne P., Evans A.C., et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc. Natl. Acad. Sci. USA 91 (1994) 11651-11654
170. Reynolds G.P. Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia. Nature 305 (1983) 527-529
171. Reynolds G.P. Beyond the dopamine hypothesis. The neurochemical pathology of schizophrenia. Br. J. Psychiatry 155 (1989) 305-316
172. Reynolds G.P., and Czudek C. Status of the dopaminergic system in post-mortem brain in schizophrenia. Psychopharmacol. Bull. 24 (1988) 345-347
173. Reynolds G.P., and Mason S.L. Are striatal dopamine D4 receptors increased in schizophrenia?. J. Neurochem. 63 (1994) 1576-1577
174. Reynolds G.P., Czudek C., Bzowej N., and Seeman P. Dopamine receptor asymmetry in schizophrenia. Lancet 1 (1987) 979
175. Ridray S., Griffon N., Mignon V., Souil E., Carboni S., Diaz J., Schwartz J.C., and Sokoloff P. Coexpression of dopamine D1 and D3 receptors in islands of Calleja and shell of nucleus accumbens of the rat: Opposite and synergistic functional interactions. Eur. J. Neurosci. 10 (1998) 1676-1686
176. Robertson G.S., Matsumura H., and Fibiger H.C. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J. Pharmacol. Exp. Ther. 271 (1994) 1058-1066
177. Robinson T.E., and Becker J.B. Enduring changes in brain and behavior produced by chronic amphetamine administration: A review and evaluation of animal models of amphetamine psychosis. Brain Res. Rev. 11 (1986) 157-198
178. Rollema H., Lu Y., Schmidt A.W., Sprouse J.S., and Zorn S.H. 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol. Psychiatry 48 (2000) 229-237
179. Ruiz J., Gabilondo A.M., Meana J.J., and Garcia-Sevilla J.A. Increased [3H] raclopride binding sites in postmortem brains from schizophrenic violent suicide victims. Psychopharmacology (Berl.) 109 (1992) 410-414
180. Sato M., Chen C.C., Akiyama K., and Otsuki S. Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis. Biol. Psychiatry 18 (1983) 429-440
181. Schoots O., Seeman P., Guan H.C., Paterson A.D., and Van Tol H.H. Long-term haloperidol elevates dopamine D4 receptors by 2-fold in rats. Eur. J. Pharmacol. 289 (1995) 67-72
182. Scott L., Kruse M.S., Forssberg H., Brismar H., Greengard P., and Aperia A. Selective up-regulation of dopamine D1 receptors in dendritic spines by NMDA receptor activation. Proc. Natl. Acad. Sci. USA 99 (2002) 1661-1664
183. Seeman P. Brain dopamine receptors in schizophrenia: PET problems. Arch. Gen. Psychiatry 45 (1988) 598-600
184. Seeman P., and Lee T. Antipsychotic drugs: Direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188 (1975) 1217-1219
185. Seeman P., Ulpian C., Bergeron C., Riederer P., Jellinger K., Gabriel E., Reynolds G.P., and Tourtellotte W.W. Bimodal distribution of dopamine receptor densities in brains of schizophrenics. Science 225 (1984) 728-731
186. Seeman P., Bzowej N.H., Guan H.C., Bergeron C., Reynolds G.P., Bird E.D., Riederer P., Jellinger K., and Tourtellotte W.W. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology 1 (1987) 5-15
187. Seeman P., Guan H.C., and Niznik H.B. Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: Implications for positron emission tomography of the human brain. Synapse 3 (1989) 96-97
188. Seeman P., Guan H.C., and Van Tol H.H. Dopamine D4 receptors elevated in schizophrenia. Nature 365 (1993) 441-445
189. Seamans J.K., Gorelova N., Durstewitz D., and Yang C.R. Bidirectional dopamine modulation of GABAergic inhibition in prefrontal cortical pyramidal neurons. J. Neurosci. 21 (2001) 3628-3638
190. Smiley J.F., Levey A.I., Ciliax B.J., and Goldman-Rakic P.S. D1 dopamine receptor immunoreactivity in human and monkey cerebral cortex: Predominant and extrasynaptic localization in dendritic spines. Proc. Natl. Acad. Sci. USA 91 (1994) 5720-5724
191. Smith A.D., and Bolam J.P. The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones. Trends Neurosci. 13 (1990) 259-265
192. Sokoloff P., Giros B., Martres M.P., Bouthenet M.L., and Schwartz J.C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347 (1990) 146-151
193. Sokoloff P., Diaz J., Levesque D., Pilon C., Dimitriadou V., Griffon N., Lammers C.H., Martres M.P., and Schwartz J.C. Novel dopamine receptor subtypes as targets for antipsychotic drugs. Ann. N. Y. Acad. Sci. 757 (1995) 278-292
194. Spano P.F., Govoni S., and Trabucchi M. Studies on the pharmacological properties of dopamine receptors in various areas of the central nervous system. Adv. Biochem. Psychopharmacol. 19 (1978) 155-165
195. Starr M.S. Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease. Synapse 19 (1995) 264-293
196. Sumiyoshi T., Stockmeier C.A., Overholser J.C., Thompson P.A., and Meltzer H.Y. Dopamine D4 receptors and effects of guanine nucleotides on [3H]raclopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depression. Brain Res. 681 (1995) 109-116
197. Sunahara R.K., Guan H.C., O'Dowd B.F., Seeman P., Laurier L.G., Ng G., George S.R., Torchia J., Van Tol H.H., and Niznik H.B. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature 350 (1991) 614-619
198. Surmeier D.J., Eberwine J., Wilson C.J., Cao Y., Stefani A., and Kitai S.T. Dopamine receptor subtypes colocalize in rat striatonigral neurons. Proc. Natl. Acad. Sci. USA 89 (1992) 10178-10182
199. Surmeier D.J., Song W.J., and Yan Z. Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J. Neurosci. 16 (1996) 6579-6591
200. Takahashi M., Shirakawa O., Toyooka K., Kitamura N., Hashimoto T., Maeda K., Koizumi S., Wakabayashi K., Takahashi H., Someya T., and Nawa H. Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol. Psychiatry 5 (2000) 293-300
201. Talbot P.S., and Laruelle M. The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development. Eur. Neuropsychopharmacol. 12 (2002) 503-511
202. Tarazi F.I., Florijn W.J., and Creese I. Differential regulation of dopamine receptors after chronic typical and atypical antipsychotic drug treatment. Neuroscience 78 (1997) 985-996
203. Taylor S.F., Koeppe R.A., Tandon R., Zubieta J.K., and Frey K.A. In vivo measurement of the vesicular monoamine transporter in schizophrenia. Neuropsychopharmacology 23 6 (2000) 667-675
204. Tiberi M., Jarvie K.R., Silvia C., Falardeau P., Gingrich J.A., Godinot N., Bertrand L., Yang-Feng T.L., Fremeau Jr. R.T., and Caron M.G. Cloning, molecular characterization, and chromosomal assignment of a gene encoding a second D1 dopamine receptor subtype: Differential expression pattern in rat brain compared with the D1A receptor. Proc. Natl. Acad. Sci. USA 88 (1991) 7491-7495
205. Torstenson R., Hartvig P., Langstrom B., Bastami S., Antoni G., and Tedroff J. Effect of apomorphine infusion on dopamine synthesis rate relates to dopaminergic tone. Neuropharmacology 37 (1998) 989-995
206. Tune L.E., Dean F., Wong D.F., Pearlson G., Strauss M., Young T., Shaya E.K., Dannals R.F., Wilson A.A., Ravert H.T., Sapp J., Cooper T., et al. Dopamine D2 receptor density estimates in schizophrenia: A positron emission tomography study with 11C-N-methylspiperone. Psychiatry Res. 49 (1993) 219-237
207. Tzschentke T.M. Pharmacology and behavioral pharmacology of the mesocortical dopamine system. Prog. Neurobiol. 63 (2001) 241-320
208. Van Tol H.H., Bunzow J.R., Guan H.C., Sunahara R.K., Seeman P., Niznik H.B., and Civelli O. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350 (1991) 610-614
209. Villemagne V.L., Wong D.F., Yokoi F., Stephane M., Rice K.C., Matecka D., Clough D.J., Dannals R.F., and Rothman R.B. GBR12909 attenuates amphetamine-induced striatal dopamine release as measured by [(11)C]raclopride continuous infusion PET scans. Synapse 33 (1999) 268-273
210. Weickert C.S., Hyde T.M., Lipska B.K., Herman M.M., Weinberger D.R., and Kleinman J.E. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol. Psychiatry 8 (2003) 592-610
211. Weinberger D., and Laruelle M. Neurochemical and neuropharmachological imaging in schizophrenia. In: Davis K.L., Charney D.S., Coyle J.T., and Charles Nemeroff (Eds). "Neuropsychopharmacology: The Fifth Generation of Progress" (2001), Lippincott, Williams, and Wilkins, New York 833-856
212. Weinberger D.R. Implications of the normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry 44 (1987) 660-669
213. Weinberger D.R., Berman K.F., and Chase T.N. Mesocortical dopaminergic function and human cognition. Ann. N. Y. Acad. Sci. 537 (1988) 330-338
214. West A.R., and Grace A.A. Opposite influences of endogenous dopamine D1 and D2 receptor activation on activity states and electrophysiological properties of striatal neurons: Studies combining in vivo intracellular recordings and reverse microdialysis. J. Neurosci. 22 (2002) 294-304
215. Wilkinson L.S. The nature of interactions involving prefrontal and striatal dopamine systems. J. Psychopharmacol. 11 (1997) 143-150
216. Wilson C.J., and Kawaguchi Y. The origins of two-state spontaneous membrane potential fluctuations of neostriatal spiny neurons. J. Neurosci. 16 (1996) 2397-2410
217. Wong D.F., Wagner Jr. H.N., Tune L.E., Dannals R.F., Pearlson G.D., Links J.M., Tamminga C.A., Broussolle E.P., Ravert H.T., Wilson A.A., Toung J.K., Malat J., et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 234 (1986) 1558-1563
218. Yang C.R., Seamans J.K., and Gorelova N. Developing a neuronal model for the pathophysiology of schizophrenia based on the nature of electrophysiological actions of dopamine in the prefrontal cortex. Neuropsychopharmacology 21 (1999) 161-194
219. Yang Y.K., Yu L., Yeh T.L., Chiu N.T., Chen P.S., and Lee I.H. Associated alterations of striatal dopamine D2/D3 receptor and transporter binding in drug-naive patients with schizophrenia: A dual-isotope SPECT study. Am. J. Psychiatry 161 (2004) 1496-1498
220. Young D., and Scoville W.B. Paranoid psychosis in narcolepsy and the possible dangers of benzedrine treatment. Med. Cli. North Am. 22 (1938) 637
221. Youngren K.D., Inglis F.M., Pivirotto P.J., Jedema H.P., Bradberry C.W., Goldman-Rakic P.S., Roth R.H., and Moghaddam B. Clozapine preferentially increases dopamine release in the rhesus monkey prefrontal cortex compared with the caudate nucleus. Neuropsychopharmacology 20 (1999) 403-412
222. Zhou Q.Y., Grandy D.K., Thambi L., Kushner J.A., Van Tol H.H., Cone R., Pribnow D., Salon J., Bunzow J.R., and Civelli O. Cloning and expression of human and rat D1 dopamine receptors. Nature 347 (1990) 76-80
223. Zhu M.Y., Juorio A.V., Paterson I.A., and Boulton A.A. Regulation of striatal aromatic L-amino acid decarboxylase: Effects of blockade or activation of dopamine receptors. Eur. J. Pharmacol. 238 (1993) 157-164